Showing results (191-200 of 278) with videos related to
Sort By:
Pageof 28
Experimental Pathology|January 1, 1987
Carcinogenicity studies on fibres, metal compounds, and some other dusts in ratsF Pott, U Ziem, F J Reiffer, et al.Rheumatology (Oxford, England)|October 9, 1999
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?A Calin, J P Nakache, A Gueguen, et al.Anesthesiology|April 28, 2022
Advances in Neuroimaging and Monitoring to Defend Cerebral Perfusion in Noncardiac SurgeryJonathon P Fanning, Samuel F Huth, Chiara Robba, et al.The Journal of Rheumatology|May 6, 1999
Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacityA Calin, J P Nakache, A Gueguen, et al.Annals of the New York Academy of Sciences|February 3, 1999
Effects of the anti-CD2 mAb OX34 on in vivo proliferationJ C Hoffmann, C Herklotz, M Zeitz, et al.Klinische Wochenschrift|February 15, 1988
Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter studyM Schattenkirchner, H Bröll, B Kaik, et al.Zeitschrift Fur Rheumatologie|March 15, 2006
[Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components]S Merkesdal, J L Huelsemann, T Mittendorf, et al.Clinical Rheumatology|December 1, 1990
A three year comparative study of auranofin and gold sodium thiomalate in rheumatoid arthritisR Rau, M Schattenkirchner, H Muller-Fassbender, et al.Annals of the Rheumatic Diseases|March 13, 1998
Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34J C Hoffmann, C Herklotz, H Zeidler, et al.Clinical and Experimental Rheumatology|September 1, 1996
Requirements for HLA-B*2705-binding peptides with special regard to the transporter associated with antigen processing (TAP)J G Kuipers, R Raybourne, K M Williams, et al.Pageof 28